SWOG clinical trial number
SWOG-9449 (INT-0156) (E1C93)

Phase II Study of VIP (Etoposide, Ifosfamide and Cisplatin) in the Treatment of Invasive Thymoma

Closed
Phase
Published
Abbreviated Title
Phase II Study of VIP (Etoposide, Ifosfamide and Cisplatin) in the Treatment of Invasive Thymoma
Activated
09/01/1995
Closed
02/27/1997

Research committees

Lung Cancer

Publication Information Expand/Collapse

2001

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial

PJ Loehrer;M Jiroutek;S Aisner;J Aisner;M Green;CR Thomas;R Livingston;DH Johnson Cancer 91(11):2010-2015

1998

Phase II trial of etoposide (V), ifosfamide (I) plus cisplatin (P) in patients with advanced thymoma (T) or thymic carcinoma (TC): Preliminary results from an ECOG coordinated intergroup trial.

PJ Loehrer;M Jiroutek;S Aisner;J Aisner;MR Greene;CR Thomas Jr;RB Livingston;DH Johnson Proc of the American Society of Clinical Oncology 17:30a(#118)

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase